India:EQBIOCON

Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024

* Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports interchangeability between adalimumab and adalimumab-fkjp * Biosimilarity between Bmab 1200 and reference biologic-Ustekinumab in pivotal Phase 3 trial in patients with moder...

2024-09-25 13:21 1283

Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan

BENGALURU, India, Aug. 29, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the Company has signed a settlement and license agreement with Janssen Biotech Inc., Janss...

2024-08-29 13:38 1634

Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

BENGALURU, India, Feb. 9, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, ...

2024-02-09 11:22 2508

Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe

BENGALURU, India, Dec. 1, 2023 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris' biosimilars business in 31 European countries has been successfully completed. Following the acquisition of ...

2023-12-01 03:53 1787

Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North America Ahead of Schedule

BRIDGEWATER, N.J. and BENGALURU, India, Sept. 6, 2023 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the Company has completed the integration of the acquired biosimilars business from Viatris inNorth America (United St...

2023-09-06 19:00 1614

Week's Top Stories